Prognostic impact of bronchoalveolar lavage galactomannan and Aspergillus culture results on survival in COVID-19 ICU patients: a post-hoc analysis from the European Confederation of Medical Mycology (ECMM) COVID-19-associated pulmonary aspergillosis (CAPA) Study

Research output: Contribution to journalArticlepeer-review

  • External authors:
  • Daniele Roberto Giacobbe
  • Juergen Prattes
  • Joost Wauters
  • Silvia Dettori
  • Alessio Signori
  • Jon Salmanton‐garcía
  • Johan Maertens
  • Marc Bourgeois
  • Marijke Reynders
  • Lynn Rutsaert
  • Niels Van Regenmortel
  • Piet Lormans
  • Simon Feys
  • Nikolay Klimko
  • Olga Shadrivova
  • Oliver A Cornely
  • Philipp Koehler
  • Katrien Lagrou
  • Matteo Bassetti
  • Martin Hoenigl

Abstract

Critically ill patients with coronavirus disease 2019 (COVID-19) may develop COVID-19-associated pulmonary aspergillosis (CAPA), that impact their chances of survival. Whether positive bronchoalveolar lavage fluid (BALF) mycological tests can be used as a survival proxy remains unknown. We conducted a post-hoc analysis of a previous multicenter, multinational observational study with the aim of assessing the differential prognostic impact of BALF mycological tests, namely positive (≥ 1.0 optical density index) BALF galactomannan (GM) and positive BALF Aspergillus culture alone or in combination in critically ill patients with COVID-19. Of the 592 patients critically ill patients with COVID-19 enrolled in the main study, 218 were included in this post-hoc analysis as they had both test results available. CAPA was diagnosed in 56/218 patients (26%). Most cases were probable CAPA (51/56, 91%) and fewer were proven CAPA (5/56, 9%). In the final multivariable model adjusted for between-center heterogeneity, an independent association with 90-day mortality was observed for the combination of positive BALF GM and positive BALF Aspergillus culture in comparison with both tests negative (hazard ratio 2.53, 95% CI 1.28-5.02, p = 0.008). The other independent predictors of 90-day mortality were increasing age and active malignant disease. In conclusion, the combination of positive BALF GM and positive BALF Aspergillus culture was associated with increased 90-day mortality in critically ill patients with COVID-19. Additional study is needed to explore the possible prognostic value of other BALF markers.

Key words: CAPA; GM; biomarker; galactomannan; Aspergillus; COVID-19; BALF.

Bibliographical metadata

Original languageEnglish
JournalJournal of clinical microbiology
Publication statusAccepted/In press - 15 Feb 2022